RxDoctor Payments Data

Daniel Orr, MD

Family Medicine · Chester Springs, PANPI 1891846614

Payments from drug & device makers

$39,352in general payments, 2019–2025

Across 712 payments — averaging $55.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$24K
  • Ironshore Pharmaceuticals Inc.$4K
  • Lilly USA, LLC$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Corium, LLC$839
  • Supernus Pharmaceuticals, Inc.$826
  • plus $7K from 32 others

What the payments were for

  • Consulting fees$2,1906%
  • Speaking & faculty fees$20,72053%
  • Travel & lodging$2,1225%
  • Food & beverage$14,22936%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,352 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,152
Medicare patients
159
Services billed
1,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$140,836
Tresiba Flextouch U-200Insulin Degludec43$44,613
EliquisApixaban28$40,311
OzempicSemaglutide22$32,639
JardianceEmpagliflozin35$30,211
Nurtec OdtRimegepant Sulfate12$21,117
FarxigaDapagliflozin Propanediol23$19,374
TrintellixVortioxetine Hydrobromide24$13,689
LinzessLinaclotide16$12,472
Breo ElliptaFluticasone/Vilanterol17$9,676
VyvanseLisdexamfetamine Dimesylate14$8,508
Repatha SureclickEvolocumab12$6,602
Lisdexamfetamine Dimesylate13$5,340
MyrbetriqMirabegron12$4,885
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$4,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,672$140,836104 claims
PfizerEliquis, Nurtec Odt, Paxlovid$511$62,85855 claims
Novo NordiskOzempic$811$32,63922 claims
Boehringer IngelheimJardiance$211$30,21135 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$190$22,19738 claims
AstraZenecaFarxiga$665$19,37423 claims
AbbVieLinzess, Synthroid$24,067$15,72257 claims
GSKBreo Ellipta$76$9,67617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Chester Springs

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →